Fibrocell Science (FCSC) Sees Large Volume Increase

Share on StockTwits

Shares of Fibrocell Science Inc (NASDAQ:FCSC) saw unusually-strong trading volume on Monday . Approximately 31,266,320 shares traded hands during mid-day trading, an increase of 3,847% from the previous session’s volume of 792,110 shares.The stock last traded at $2.54 and had previously closed at $1.78.

A number of research analysts have weighed in on FCSC shares. Zacks Investment Research lowered shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Fibrocell Science in a research note on Thursday, March 28th. Finally, ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.

The company has a market cap of $21.57 million, a price-to-earnings ratio of -1.46 and a beta of 1.59.

Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.48. Equities analysts forecast that Fibrocell Science Inc will post -1.38 EPS for the current fiscal year.

A hedge fund recently raised its stake in Fibrocell Science stock. Renaissance Technologies LLC lifted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 126.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 367,941 shares of the company’s stock after purchasing an additional 205,660 shares during the period. Renaissance Technologies LLC owned 3.95% of Fibrocell Science worth $868,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4299422/fibrocell-science-fcsc-sees-large-volume-increase.html.

About Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Featured Story: How do candlesticks reflect price movement?

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Braemar Hotels & Resorts   Receives $14.67 Average Price Target from Brokerages
Braemar Hotels & Resorts Receives $14.67 Average Price Target from Brokerages
Linkey  Hits Market Capitalization of $29.56 Million
Linkey Hits Market Capitalization of $29.56 Million
Brokerages Set STEP Energy Services Ltd  Target Price at $6.89
Brokerages Set STEP Energy Services Ltd Target Price at $6.89
LemoChain  Market Cap Reaches $0.00
LemoChain Market Cap Reaches $0.00
Nexoptic Technology  Stock Price Up 12.5%
Nexoptic Technology Stock Price Up 12.5%
DROXNE  Price Tops $0.0003 on Exchanges
DROXNE Price Tops $0.0003 on Exchanges


© 2006-2019 Ticker Report